Polianta Ltd Purchases Shares of 21,000 Globus Medical, Inc. $GMED

Key Points

• Polianta Ltd acquired 21,000 Globus Medical shares in the second quarter, worth approximately $1.66 million. Institutional investors collectively own 95.16% of the company.
• Globus Medical’s latest quarter surpassed expectations, with adjusted EPS of $1.34 and revenue of $789.6 million, up 5.9% year over year. Management raised fiscal 2026 EPS guidance to $4.95–$5.05 while keeping revenue guidance near $3.2 billion.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $101.77, though execution risks and a recent insider sale of 25,000 shares present cautionary signals.

Polianta Ltd acquired a new position in shares of Globus Medical, Inc. (NYSE:GMED - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 21,000 shares of the medical device company's stock, valued at approximately $1,659,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Janus Henderson Group PLC raised its holdings in Globus Medical by 4.5% during the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company's stock worth $656,831,000 after purchasing an additional 328,217 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Globus Medical by 1,235.2% in the 4th quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company's stock valued at $339,322,000 after buying an additional 3,595,339 shares in the last quarter. Bank of Montreal Can boosted its holdings in shares of Globus Medical by 15,317.1% in the 4th quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company's stock valued at $294,519,000 after buying an additional 3,351,380 shares in the last quarter. Sculptor Capital LP grew its position in shares of Globus Medical by 1.9% in the 1st quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company's stock valued at $263,477,000 after buying an additional 58,000 shares during the last quarter. Finally, Madison Avenue Partners LP grew its position in shares of Globus Medical by 3.0% in the 4th quarter. Madison Avenue Partners LP now owns 2,624,751 shares of the medical device company's stock valued at $229,167,000 after buying an additional 76,588 shares during the last quarter. Institutional investors and hedge funds own 95.16% of the company's stock.

Insider Buying and Selling at Globus Medical

In other news, Director David D. Davidar sold 25,000 shares of the stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the sale, the director owned 510,175 shares in the company, valued at approximately $41,201,733. This represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 18.38% of the company's stock.

Trending Headlines about Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Q2 results exceeded expectations: Globus Medical reported adjusted earnings of $1.34 per share, ahead of the approximately $1.10–$1.12 consensus, while revenue reached $789.6 million versus estimates of $782.9 million. Revenue increased 5.9% year over year, and EPS rose substantially from $0.86 in the prior-year quarter. Globus Medical Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Profit outlook improved: Management raised its fiscal 2026 EPS guidance to $4.95–$5.05, above the prior analyst consensus of $4.74. The earnings call highlighted margin gains, spine-market growth and continued benefits from operating leverage. GMED Q2 Earnings Call Highlights
• Positive Sentiment: Analyst support remains favorable: TD Cowen maintained a Buy rating and a $115 price target, citing reaccelerating spine growth, strong earnings power and robust research-and-development investment. Globus Medical Earns Buy Rating
• Neutral Sentiment: Sales outlook was unchanged: Globus Medical kept fiscal 2026 revenue guidance near $3.2 billion, roughly in line with consensus. This limits the upside from the earnings report but indicates management is maintaining its growth expectations.
• Negative Sentiment: Some execution risks remain: Management cited risks involving Nevro and Enabling Technologies, contributing to caution around revenue growth. Wells Fargo also lowered its price target from $103 to $99, although it retained an Overweight rating. Wells Fargo Analyst Action

Globus Medical Price Performance

GMED stock opened at $82.20 on Friday. The company has a fifty day moving average price of $79.33 and a 200 day moving average price of $85.23. Globus Medical, Inc. has a 12 month low of $54.15 and a 12 month high of $101.40. The company has a market cap of $11.16 billion, a price-to-earnings ratio of 21.02, a price-to-earnings-growth ratio of 1.70 and a beta of 0.95.

Globus Medical (NYSE:GMED - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, topping analysts' consensus estimates of $1.10 by $0.24. Globus Medical had a net margin of 17.02% and a return on equity of 14.73%. The firm had revenue of $789.61 million during the quarter, compared to analysts' expectations of $782.88 million. During the same quarter in the prior year, the business earned $0.86 EPS. Globus Medical's quarterly revenue was up 5.9% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, analysts anticipate that Globus Medical, Inc. will post 5 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on GMED shares. Zacks Research cut shares of Globus Medical from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 6th. Stifel Nicolaus cut their target price on Globus Medical from $95.00 to $80.00 and set a "hold" rating on the stock in a research report on Wednesday, July 8th. Royal Bank Of Canada reduced their target price on Globus Medical from $120.00 to $115.00 and set an "outperform" rating for the company in a report on Monday, July 13th. Needham & Company LLC upped their target price on Globus Medical from $114.00 to $117.00 and gave the company a "buy" rating in a research report on Friday, May 8th. Finally, Weiss Ratings restated a "hold (c+)" rating on shares of Globus Medical in a research note on Monday, July 13th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $101.77.

About Globus Medical

Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical, Inc. (NYSE:GMED - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source